Treatment of Psoriasis Using Efalizumab

Therapy of Moderate-to-Severe Psoriasis, Second Edition, Revised and Expanded

Volumn , Issue , 2003, Pages 333-350

  Leonardi, Craig L ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 1242291466     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b14220-19     Document Type: Chapter

References (27)

1. Nickoloff BJ. The immunologic and genetic basis of psoriasis. Arch Dermatol 1999; 135:1104–1110.
2. Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999; 20:40–46.
3. Reiser H, Stadecker MJ. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune disease. N Engl J Med 1996; 335:1369–1377.
4. Grakoui A, Bromley SK, Sumen C, Davis MM, Shaw AS, Allen PM, et al. The immunological synapse: A molecular machine controlling T cell activation. Science 1999;285:221–227.
5. Marlin SD, Springer TA. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell 1987; 51:813–819.
6. Sanders ME, Makgoba MW, Sharrow SO, Stephany D, Springer TA, Young HA, Shaw S. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-g production. J Immunol 1988; 140:1401–1407.
7. Nickoloff BJ, Basham TY, Merigan TC, Morhenn VB. Keratinocyte class II histocompatibility antigen expression. Br J Dermatol 1985; 112:373–374.
8. van Seventer GA, Shimizu Y, Horgan KJ, Luce GE, Webb D, Shaw S. Remote T cell co-stimulation via LFA-1/ICAM-1 and CD2/LFA-3: demonstration with immobilized ligand/mAb and implication in monocyte-mediated co-stimulation. Eur J Immunol 1991; 21:1711–1718.
9. Nickoloff BJ, Griffiths CEM, Barker JNWN. The role of adhesion molecules, chemotactic factors, and cytokines in inflammatory and neoplastic skin disease—1990 update. J Invest Dermatol 1990; 94:151S–157S.
10. Nickoloff BJ, Mitra RS, Green J, Zheng X-G, Shimizu Y, Thompson C, Turka LA. Accessory cell function of keratinocytes for superantigens. J Immunol 1993; 150:2148–2159.
11. Hildreth JE, Gotch FM, Hildreth PD, McMichael AJ. A human lymphocyteassociated antigen involved in cell-mediated lympholysis. Eur J Immunol 1983; 13:202–208.
12. Werther WA, Gonzalez TN, O’Connor SJ, McCabe S, Chan B, Hotaling T, Champe M, Fox JA, Jardieu PM, Berman PW, Presta LG. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 1996; 157:4986–4995.
13. Klingbeil C, Hsu DH. Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use. Toxicol Pathol 1999; 27:1–3.
14. Krueger J, Gottlieb A, Miller B, et al. Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking. J Invest Dermatol 2000;115:333.
15. Lowe J, Stefanich E, Rangell L, Pippig S. Efalizumab (anti-CD11a) inhibits transendothelial migration of T cells. Poster Presented at Society of Investigative Dermatology, Los Angeles, California, May 15–18, 2002.
16. Bauer RJ, Dedrick RL, White ML, Murray MJ, Garovoy MR. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human patients with psoriasis. J Pharmacokinet Biopharm 1999; 27:397–420.
17. Gottlieb A, Krueger JG, Bright R, Ling M, Lebwohl M, Kang S, Feldman S, Spellman M, Wittkowski K, Ochs HD, Jardieu P, Bauer R, White M, Dedrick R, Garovoy M. Effects of administration of a single dose of humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000; 42:428–435.
18. Papp K, Bissonnette R, Krueger JG, Carey W, Gratton D, Gulliver WP, Lui H, Lynde CW, Magee A, Minier D, Ouellet JP, Patel P, Shapiro J, Shear NH, Kramer S, Walicke P, Bauer R, Dedrick RL, Kim SS, White M, Garovoy M The treatment of moderate to severe plaque psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001; 45:665–674.
19. Gottlieb AB, Miller B, Chaudhari U, Oh C, Sherr A, Solodkina G, et al. Clinical and histologic effects of subcutaneously administered anti-CD11a (hu1124) in patients with psoriasis. Poster Presented at Society of Investigative Dermatology, Chicago Illinois, May 10, 1999.
20. Dummer W, Joshi A, Beyer J, Garovoy M, Dedrick R, Krueger J, Gottlieb AB, Bauer RJ. Pharmacodynamic effects of subcutaneous (SC) administration of efalizumab (anti-CD11a). 60th Annual Meeting of the American Academy of Dermatology, New Orleans, LA, Feb 22–27, 2002.
21. Leonardi CL, Gottlieb AB, Miller B, Tashjian D, Pariser D, Shapiro W, et al. Efalizumab (anti-CD11a): results of a 12 week trial of subcutaneous administration in patients with moderate to severe plaque psoriasis. Poster Presented at American Association of Dermatology, Washington D.C., March 2–7, 2001.
22. Menter A, Bissonnette R, Gottlieb AB, Goffe B, Beutner KR, Dunlap R, Magee A, Dummer W, Papp KA. Subcutaneous efalizumab (anti-CD11a) provides rapid clinical response in patients with moderate to severe plaque psoriasis. 60th Annual Meeting of the American Academy of Dermatology, New Orleans, LA, Feb 22–27, 2002.
23. Gottlieb AB, Papp KA, Lynde CW, Carey W, Powers J, Rist TE, Rafal E, McCune M, Shear NH, Ouellet JP, Walicke P, Compton P, Tyring S, Garovoy M, Leonardi C. Subcutaneous efalizumab (anti-CD11a) is effective in the treatment of moderate to severe plaque psoriasis: pooled results of 2 phase III clinical trials. 60th Annual Meeting of the American Academy of Dermatology, New Orleans, LA, Feb 22–27, 2002.
24. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine use. Clin Exp Dermatol 1994;19:210–216.
25. Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996;107:707–713.
26. Gordon KB, Leonardi C, Harvey D, Powers J, Phillips H, Weinstein GD, Compton P, Dummer W, Lowe N. Continuous treatment improves outcomes in patients with moderate to severe plaque psoriasis treated with subcutaneous (SC) efalizumab (anti-CD11a): results from the phase III trial ACD2058g. 60th Annual Meeting of the American Academy of Dermatology, New Orleans, LA, Feb 22–27, 2002.
27. Lebwohl M, Miller JL, Goldman M, Henderson D, Nelson C, Wolf D, Chambers M, Gilbert M, Farber H, Clark S, Edwards L, Stein LF, Wang X, Dummer W, Koo JY. Continued treatment with subcutaneous efalizumab (anti-CD11a) improves outcome in patients with moderate to severe plaque psoriasis. 60th Annual Meeting of the American Academy of Dermatology, New Orleans, LA, Feb 22–27, 2002.